Document Detail


Treatment of metastatic uveal melanoma with intravenous fotemustine.
MedLine Citation:
PMID:  23624366     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52% of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44%). The median survival duration was 13.9 months, and the 1-year survival rate was 60%. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.
Authors:
Francesco Spagnolo; Marco Grosso; Virginia Picasso; Elena Tornari; Marianna Pesce; Paola Queirolo
Related Documents :
24056206 - Proteomics in uveal melanoma.
10211756 - Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
23009726 - Bevacizumab and erlotinib (be) first-line therapy in advanced non-squamous non-small-ce...
23846936 - Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
6403716 - Influence of thiotepa and doxorubicin instillation at time of transurethral surgical tr...
10647616 - Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conj...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Melanoma research     Volume:  23     ISSN:  1473-5636     ISO Abbreviation:  Melanoma Res.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-04-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  196-8     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale Per La Ricerca Sul Cancro, Genova, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria-endemic...
Next Document:  Impaired PIASy-Tip60 signaling weakens activation of p53 in melanoma.